Page 319 - ebook HCC

PROGRAMME
GENEV
EASL HCC SUMMITHCC SUMMIT
317
316 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 317
316
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C81
HBV DNA INTEGRATION IN PATIENTS
WITH OCCULT HBV INFECTION AND
HEPATOCELLULAR CARCINOMA

Carlo Saitta , Teresa Pollicino , Giuseppina Raffa , Antonio Bertuccio , In all cases viral integration appeared randomly distributed throughout the host genome.
1
1
1
1
Marika Lanza , Gianluca Tripodi , Adalberto Barbera , Angelo Sangiovanni , X gene sequences were found in 17 cases, preS-S regions in 14 cases, preCore-Core
1
3
1
2
Antonina Smedile , Giuseppe Navarra , Giovanni Raimondo 1 region in 6 cases.
4
2
1 Internal Medicine, Unit of Clinical and Molecular Hepatology - University Hospital of Neither β-catenin nor TP53 mutations were revealed in any case. In addition, Arg72Pro
2
Messina, Uman Pathology, Unit of Oncological Surgery - University Hospital of Messina, TP 53 polymorphism was equally distributed in the different sub-groups evaluated
Messina, Medicine, Division of Gastroenterology - Fondazione IRCCS Cà Granda independently of occult or overt HBV infection and HBV DNA integration. No case had the
3
4
Ospedale Maggiore Policlinico , Milan, Internal Medicine, Gastro-Hepatology Unit - Arg249Ser TP53 polymorphism.
University Hospital of Turin, Turin, Italy
Conclusion: HBV DNA integration is a frequent finding in tumour tissues from patients
Corresponding author’s e-mail: csaitta@unime.it with OBI as well as overt infection. X and preS/S are the viral genomic regions more often
involved in the integration process. Integrations occur at level of regulatory and functional
genes in most cases. Our findings indicate that viral integration may exert a pathogenic
Introduction: HBV DNA integration into the cellular genome is an important pro-oncogenic role in hepatocarcinogenesis in all HBV-infected cases independently of the HBsAg status
event in chronic HBV infected patients. Viral integration may occur also in HBsAg-negative as well as of the β-catenin and TP53 genetics. OBI testing may allow the identification of
patients with occult HBV infection (OBI), although extensive studies have not been HBsAg negative patients with higher risk of developing HCC.
performed in this field.
Aims: Our aim was to investigate and characterize HBV DNA integration and to perform
a genetic analysis of β-catenin and TP53 in tumours from OBI patients with hepatocellular
carcinoma (HCC).
Methodology: Frozen tumour specimens from 69 HCC Italian patients were examined
CLINICAL POSTER ABSTRACTS to reveal HBV DNA integration into the host genome. The molecular characterization of the CLINICAL POSTER ABSTRACTS
(49 OBI-positive diagnosed by HBV DNA detection in liver tissue, 10 HBsAg-positive, 10
HBsAg-negative/OBI-negative). Tumour DNA extracts were studied by Alu-PCR technique
virus-genome junctions was performed by cloning and sequencing analyses. Furthermore,
PCR amplification and direct sequencing of exon 3 of β-catenin and of the entire TP53
gene were performed.
Results: Integrated HBV DNA was detected in 37/49 (75.5%) OBI-positive HCC samples,
in 8/10 (80%) tumours from HBsAg-positive patients and in 0/10 OBI-negative HCC
samples. In 64% of OBI cases, HBV integrants were found in intergenic regions of human
genome, while in 36% they were located in intragenic regions, including genes involved in
cell growth and adhesion, angiogenesis and cell signalling.